Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 4.69 is 44% below its 3-year average of 8.35, near the low end of its 3-year range (0.00–90.42).
As of the fiscal period ended Tuesday, June 30, 2026. 43.51% below its 12-month average of 8.31.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.69.
QUICK RATIO (ACID-TEST)
4.69
QUICK RATIO (ACID-TEST) AVG TTM
8.31
QUICK RATIO (ACID-TEST) AVG 3Y
9.11
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-43.51%
CURRENT VS 3Y AVG
-48.45%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.19
median of 736 covered companies
CURRENT VS SECTOR MEDIAN
+47.15%
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$290.39M
Quick Ratio (Acid-Test)
4.69
TTM Avg
8.31
3Y Avg
9.11
5Y Avg
N/A
Market Cap
$288.21M
Quick Ratio (Acid-Test)
6.40
TTM Avg
6.41
3Y Avg
5.95
5Y Avg
4.92
Market Cap
$286.63M
Quick Ratio (Acid-Test)
8.80
TTM Avg
4.55
3Y Avg
3.67
5Y Avg
2.92
Market Cap
$295.55M
Quick Ratio (Acid-Test)
4.70
TTM Avg
5.10
3Y Avg
7.75
5Y Avg
8.34
Market Cap
$283.38M
Quick Ratio (Acid-Test)
31.35
TTM Avg
25.02
3Y Avg
20.04
5Y Avg
16.05
Market Cap
$283.11M
Quick Ratio (Acid-Test)
19.48
TTM Avg
1.73
3Y Avg
4.11
5Y Avg
4.35
Market Cap
$301.07M
Quick Ratio (Acid-Test)
34.00
TTM Avg
44.34
3Y Avg
25.02
5Y Avg
19.51
Market Cap
$278.73M
Quick Ratio (Acid-Test)
2.80
TTM Avg
2.74
3Y Avg
2.22
5Y Avg
2.48
Market Cap
$278.40M
Quick Ratio (Acid-Test)
9.22
TTM Avg
6.22
3Y Avg
4.84
5Y Avg
4.06
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $290.39M | 4.69 | 8.31 | 9.11 | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.21M | 6.40 | 6.41 | 5.95 | 4.92 |
| Standard BioTools Inc. (LAB)vs › | $286.63M | 8.80 | 4.55 | 3.67 | 2.92 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.55M | 4.70 | 5.10 | 7.75 | 8.34 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.38M | 31.35 | 25.02 | 20.04 | 16.05 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $283.11M | 19.48 | 1.73 | 4.11 | 4.35 |
| Benitec Biopharma Inc. (BNTC)vs › | $301.07M | 34.00 | 44.34 | 25.02 | 19.51 |
| Aurora Cannabis Inc. (ACB)vs › | $278.73M | 2.80 | 2.74 | 2.22 | 2.48 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $278.40M | 9.22 | 6.22 | 4.84 | 4.06 |
| Fate Therapeutics, Inc. (FATE)vs › | $276.83M | 4.85 | 6.69 | 6.56 | 6.64 |
Quick Ratio
4.69
Excludes inventory
Current Ratio
4.69
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 4.69 |
| 2026-03-31 | 6.16 |
| 2025-12-31 | 12.14 |
| 2025-09-30 | 13.33 |
| 2025-06-30 | 5.22 |
| 2025-03-31 | 5.87 |
| 2024-12-31 | 10.40 |
| 2024-09-30 | 16.12 |
| 2024-06-30 | 26.23 |
| 2024-03-31 | 90.42 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2022-12-31 | 0.00 |
